917918-83-3 Usage
Uses
Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-Methoxy-, hydrochloride (1:1) is used as a chemical intermediate for the synthesis of potential drug candidates and research chemicals. Its unique structure and functional groups make it a promising candidate for the development of new medications for various medical conditions.
The hydrochloride salt form of 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-Methoxy-, hydrochloride (1:1) is particularly advantageous in improving the solubility and stability of the molecule, which is crucial for its successful incorporation into pharmaceutical formulations. This enhanced solubility and stability allow for easier handling and formulation into dosage forms, such as tablets, capsules, or injectables, ensuring the effective delivery of the compound to patients.
Furthermore, the potential applications of 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-Methoxy-, hydrochloride (1:1) in the development of new medications can contribute to addressing various medical conditions. Its unique chemical properties and structural features may offer novel therapeutic approaches, leading to the discovery of innovative treatments and improving patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 917918-83-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,7,9,1 and 8 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 917918-83:
(8*9)+(7*1)+(6*7)+(5*9)+(4*1)+(3*8)+(2*8)+(1*3)=213
213 % 10 = 3
So 917918-83-3 is a valid CAS Registry Number.
917918-83-3Relevant academic research and scientific papers
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies
Fox, Richard J.,Tripp, Jonathan C.,Schultz, Mitchell J.,Payack, Joseph F.,Fanfair, Dayne D.,Mudryk, Boguslaw M.,Murugesan, Saravanababu,Chen, Chung-Pin H.,La Cruz, Thomas E.,Ivy, Sabrina E.,Broxer, Sévrine,Cullen, Ryan,Erdemir, Deniz,Geng, Peng,Xu, Zhongmin,Fritz, Alan,Doubleday, Wendel W.,Conlon, David A.
, p. 1095 - 1109 (2017/08/23)
The development of two enabling routes that led to the production of >1000 kg of BMS-663068 (3) is described. The route identified for the initial 100 kg delivery to support development activities and initial clinical trials involved the conversion of 2-amino-4-picoline to the parent active pharmaceutical ingredient (API), followed by pro-drug installation and deprotection. To eliminate the problematic isolation of the parent API and synthesis of di-t-butyl(chloromethyl)phosphate, a second-generation pro-drug installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ～7% overall yield.
